United States Patent 10,253,108 (Anti-HER2 Mutated Fully Human Antibody) Claims & US Patent Landscape Analysis
Executive summary: US Patent 10,253,108 claims a specific mutated, fully human anti-HER2 antibody defined by variable-region amino-acid sequences (heavy and light V regions via specified SEQ ID NO combinations), with dependent claim coverage spanning antibody formats (Fab/scFv/IgG1, etc.), IgG constant regions (human IgG1 with SEQ ID NO:5 and SEQ ID NO:6), and downstream uses including therapeutic administration, combination regimens with Herceptin (trastuzumab) or pertuzumab, pharmaceutical compositions, kits for detecting HER2, and broad HER2-positive tumor indications. The claim structure is broad at the “use/combination/kit” level but narrow at the core “molecule” level because it is sequence-defined. From an enforcement and licensing-risk standpoint, the patent’s practical reach will track whether competitors’ anti-HER2 antibodies (or biosimilar candidates) use the same V-region sequences or fall within doctrine-of-equivalents arguments around those sequence-defined elements.
What claims are in US Patent 10,253,108 (mutated fully human anti-HER2 antibody) and what do they cover?
Core claim claim-anchoring element: the independent claim (claim 1) is limited to a mutated fully human anti-HER2 antibody where the heavy-chain variable region and light-chain variable region are defined by the presence of particular SEQ ID NO pairings:
- Heavy variable region sequence is one of: SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12
- Light variable region sequence is SEQ ID NO:2 in each of the listed combinations.
In effect, claim 1 covers a family of closely related antibodies defined by (one of three heavy V sequences) + (one light V sequence), each combination being “the” claimed mutated fully human anti-HER2 antibody.
How broad is claim 1 given the SEQ ID-based definition?
- Formally broad because it includes multiple heavy V options (three heavy V sequences).
- Functionally narrow because sequence-defined variable regions are the gating element. Many “anti-HER2” antibodies will not satisfy claim 1 if they do not use the same V-region sequences (or close variants that a court might treat as equivalent).
Which claim elements create infringement “tripwires”?
- Anti-HER2 binding is expected but not written as a functional binder restriction in the claim text you provided. The limitation is defined structurally as an anti-HER2 antibody with specified sequences.
- Mutated fully human antibody: “fully human” and “mutated” are definitional qualifiers. The literal determinant still returns to the SEQ-defined V regions.
- Heavy V and light V pairing: claim 1 requires the specified combination set.
Are the claimed antibody formats (Fab/Fab’/F(ab’)2/scFv/IgG1) enough to broaden US Patent 10,253,108?
Yes at the dependent-claim level. Dependent claims (2–5) expand the physical forms and constant-region content without changing the core V-region identity.
Claim 2: formats
Claim 2 covers claim 1 antibodies “in the form of”:
This creates separate infringement hooks for commercial variants sold as fragments.
Claim 3–5: Ig constant region and IgG1 mapping
- Claim 3 requires the antibody further comprises heavy and light constant regions of human IgG.
- Claim 4 narrows to human IgG1.
- Claim 5 pins the constant regions to:
- Heavy chain constant region: SEQ ID NO:5
- Light chain constant region: SEQ ID NO:6
Practical effect: a competitor using the same V regions but swapping constant regions could evade these dependent claims while still potentially implicating claim 1 (depending on the court’s construction of whether claim 1 already requires full antibody rather than fragments). If the competitor uses the same V regions but a different IgG subclass (IgG2/IgG4) or engineered Fc, it may still fall under broader independent coverage arguments if claim 1 is construed to cover full antibodies generically.
How do the composition, combination, and kit claims expand enforcement beyond the antibody molecule?
US Patent 10,253,108 uses a standard multi-layer strategy: molecule-defined claims plus downstream product and use claims.
Claim 6: pharmaceutical composition
A pharmaceutical composition including the mutated anti-HER2 antibody of claim 1 and a pharmaceutically acceptable carrier.
- This strengthens product-form enforcement for branded drug substance/manufactured formulations.
- It also supports downstream infringement for sales of formulated antibody products even if a generic/similar entity argues an “unformulated” technicality.
Claim 7–8: combined medicament with other HER2 therapeutics
- Claim 7: combined medicament comprising the claim 1 antibody plus additional HER2-positive tumor therapeutic agent(s).
- Claim 8: specifies additional agent(s include Herceptin (trastuzumab) or pertuzumab.
Why this matters: even if a competitor’s antibody design differs at the sequence level, combination-label practices that use the claimed antibody with trastuzumab or pertuzumab create a narrow but potentially powerful infringement pathway for product packaging, kits, or combination regimens.
Claim 9: kit for detecting HER2
A kit for detecting human HER2 comprising the claim 1 antibody.
- This targets diagnostics and IVD-type reagent kits.
- For enforcement, the key is whether the kit uses the same sequence-defined V regions.
What is the method-of-treatment coverage for HER2-positive tumors under US Patent 10,253,108?
Claim 10: treating a HER2 positive tumor
A method for treating a subject with a HER2 positive tumor via administering the claim 1 antibody.
This is broad at the patient and disease level but anchored to the molecule.
Claim 11: human subjects
Confirms applicability to humans.
Claim 12: extensive indication list
Claim 12 lists a long set of cancer types and tissue sites including (non-exhaustive highlights from the text provided):
- HER2-positive breast cancer
- gastric cancer
- lung cancer / non-small cell lung cancer
- glioblastoma multiforme and related CNS tumors (as listed)
- melanoma (cutaneous or intraocular)
- lymphatic cell lymphoma and Hodgkin’s disease (as listed)
- urinary tract and genitourinary cancers (as listed)
- esophageal, thyroid, adrenal, mesothelioma, liver cell, pancreatic cancer
- multiple additional named categories
Legal/strategy point: claim 12’s breadth is a classic attempt to prevent “indication carve-outs” from defeating infringement where a competitor uses the same antibody for any listed HER2-positive tumor.
What patents protect the same “anti-HER2 fully human mutated antibody” space around US 10,253,108?
Given only the claim text you provided, the landscape analysis can be limited to claim-type mapping (not enumerating all competing US patents and their sequences). The high-probability neighboring IP categories around a sequence-defined anti-HER2 antibody patent include:
-
Variable-region sequence patents
- Antibodies are typically protected at the level of the V-region sequences, including the exact amino-acid strings and engineered variant sets.
-
Humanization / fully human antibody scaffolding patents
- Many estates around “fully human” anti-HER2 molecules include proprietary human antibody frameworks.
-
Epitope and binding-site patents
- Some patents claim antibodies that bind HER2 epitope classes, sometimes with functional binding criteria rather than strict SEQ pairs.
-
Fc engineering and effector-function modifications
- If constant regions and Fc domains are engineered for altered ADCC/complement effects, separate patents can cover those changes even when V regions are the same.
-
Formulation and dosing regimen patents
- Combination regimens with trastuzumab or pertuzumab are commonly protected as protocols, kits, and formulations.
-
Diagnostics and companion test patents
- HER2 detection kits often have dedicated antibody reagent and method patents.
Actionable takeaway: the strongest litigation posture for US 10,253,108 depends on whether competitors use the same V-region sequences or whether they use sufficiently close sequences that equivalents arguments can be sustained. If competitor V sequences diverge, separate epitope-functional patents become more relevant.
What does claim 8 (Herceptin or pertuzumab combinations) imply for licensing and settlement risk?
Claim 8 creates an enforcement vector tied to standard-of-care HER2 combination practice:
- Trastuzumab (Herceptin)
- Pertuzumab
If the claimed antibody is used in a labeled combination regimen, the patent supports:
- licensing leverage against co-formulated products,
- potential discovery into combination trial protocols and manufacturing/labeling,
- and a pathway to argue that certain commercial co-packs or kits infringe.
Critical limitation: claim 8 still requires the claimed antibody of claim 1 to be present. The combination language does not broaden claim 1; it broadens how the presence of the claimed antibody can be marketed and used.
How would biosimilar or “follow-on biologic” risk interact with a SEQ-defined antibody claim?
For biosimilars, the typical risk analysis turns on:
- whether the biosimilar’s antibody sequence matches the patented V-region sequences, and
- whether any “residual differences” can be argued as equivalent.
Here, because the independent claim is sequence-anchored to specific SEQ ID NO combinations, a biosimilar candidate is exposed primarily if it is designed on the same antibody scaffold or produced with the same V sequence identity. If it uses substantially different V regions, infringement is less likely to be literal.
What manufacturing or redesign options could avoid literal infringement of US 10,253,108?
Based on the claim structure provided:
- Avoid claim 1 by using different heavy V sequences than SEQ ID NO:10/11/12 or a light V sequence different from SEQ ID NO:2.
- If heavy and light V sequences match claim 1, redesigning only the antibody fragment format or constant regions may reduce dependent claim exposure (e.g., IgG1-specific dependent claims 4–5) but may not remove exposure under claim 1 depending on claim construction.
High-value design consideration: if a competitor tries to design around by changing constant regions (IgG1 vs other Ig subclasses), it may still face claim 1 risk if the variable regions match.
How would you map US 10,253,108 to a generic “launch scenario” for antibody therapeutics?
Unlike small molecules, antibodies are biological products and do not have “generic” pathways in the same way; the relevant risk is:
- biosimilar approval pathway (BPCIA) and interchangeability strategy, and
- litigation around sequence identity and functional equivalence.
A “launch risk” timeline is therefore driven by:
- patent expiration of claim 1’s core sequence-defined subject matter,
- any additional patent thickets on Fc, formulation, combination regimens, and diagnostics,
- and settlement or license timing.
Because this analysis is based only on the claims you provided (not the patent’s issue date, priority, expiration, or FDA approval link), no defensible exclusivity or expiration timetable can be generated here.
Key Takeaways
- US Patent 10,253,108 is molecule-centered: claim 1 is defined by specific mutated, fully human anti-HER2 antibody variable-region SEQ ID NO combinations (three heavy V options paired with a single light V sequence).
- Enforcement expands outward through dependent claims covering antibody formats (Fab/Fab’/F(ab’)2/scFv), human IgG constant regions with IgG1 fixed sequences, and downstream pharmaceutical compositions, combination medicaments with trastuzumab or pertuzumab, HER2 detection kits, and broad HER2-positive tumor treatment methods.
- Design-around is most effective at the V-region level. Changing format or constant-region details may reduce exposure to specific dependent claims but does not necessarily remove risk if claim 1’s variable regions remain matched.
- Commercial risk clusters around combination regimens and kits: claim 8 and claim 9 create targeted infringement angles tied to standard HER2 therapy combinations and detection reagent commercialization.
FAQs
1) What part of US 10,253,108 is most likely to be the infringement “core” in litigation?
Claim 1’s SEQ ID-defined heavy and light variable region pairing.
2) Can an antibody avoid dependent claims 4–5 by changing from IgG1 to another isotype?
It may avoid IgG1-specific dependent coverage, but claim 1 risk depends on whether the V-region sequences still match.
3) Does claim 8 require the additional HER2 agent to be trastuzumab or pertuzumab exclusively?
No. Claim 7 covers additional HER2-positive tumor therapeutic agents, and claim 8 specifies trastuzumab or pertuzumab as examples.
4) Are diagnostic and therapeutic uses both covered by US 10,253,108?
Yes. Claim 9 covers HER2 detection kits, and claims 10–12 cover treatment methods.
5) What is the most direct design-around for a new anti-HER2 antibody candidate?
Use different variable-region sequences that do not match the SEQ ID NO combinations required by claim 1.
References (APA)
- United States Patent 10,253,108. (claims provided in prompt).
